Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity

Background/Aim: Cardiovascular risk factors (CVRFs) predict cardiotoxicity in cancer patients but their role in late cardiac toxicity is less clear. Patients and Methods: This was a retrospective analysis of patients treated with anthracyclines (A) and/or trastuzumab (T) and a correlation with early...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2019-10, Vol.39 (10), p.5741-5745
Main Authors: CANALE, MARIA LAURA, CAMERINI, ANDREA, HUQI, ALDA, LILLI, ALESSIO, BISCEGLIA, IRMA, PARRINI, IRIS, LESTUZZI, CHIARA, DEL MEGLIO, JACOPO, DONATI, SARA, VENTURINI, ELIO, SGAMBATO, ALESSANDRO, TARANTINI, LUIGI, AMOROSO, DOMENICO, CASOLO, GIANCARLO
Format: Article
Language:English
Subjects:
Anthracycline
Cardiotoxicity
Cardiovascular diseases
Health risk assessment
Health risks
Heart
Immunotherapy
Monoclonal antibodies
Risk analysis
Risk factors
Survival
Targeted cancer therapy
Toxicity
Trastuzumab
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aim: Cardiovascular risk factors (CVRFs) predict cardiotoxicity in cancer patients but their role in late cardiac toxicity is less clear. Patients and Methods: This was a retrospective analysis of patients treated with anthracyclines (A) and/or trastuzumab (T) and a correlation with early (≤5 years) or late (>5 years) cardiac toxicity, and baseline CVRFs and CVRFs at toxicity time. Results: A total of 610 patients were included, 422 with (Group A) and 188 without (Group B) baseline CVRFs. In group A toxicity incidence was 4.7% with all events during treatment or immediately after [mean onset time 0.7 years (range=0.2-1.6)]. Events rate was 3.2% in group B with all events after five years [mean time onset 6.9 years (range=5.2-7.5)]. All group B patients who developed late cardiac toxicity presented with CVRFs at the time of toxicity not reported before. Conclusion: CVRFs could predict late cardiac toxicity and their control should be part of the survivorship program.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13775